Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation
Latest Information Update: 10 Nov 2023
At a glance
- Drugs I-131-Apamistamab (Primary) ; Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 08 Nov 2023 Results published in the Clinical Cancer Research
- 04 Oct 2021 Status changed from active, no longer recruiting to discontinued due to loss of funding.
- 15 Oct 2019 Planned End Date changed from 1 Oct 2024 to 1 Oct 2021.